U.S. markets closed

Chugai Pharmaceutical Co., Ltd. (CHGCY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
19.53-0.22 (-1.11%)
At close: 3:53PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close19.75
Open19.64
Bid0.00 x 0
Ask0.00 x 0
Day's Range19.12 - 19.64
52 Week Range17.64 - 34.90
Volume46,487
Avg. Volume63,126
Market Cap64.21B
Beta (5Y Monthly)0.67
PE Ratio (TTM)33.79
EPS (TTM)0.58
Earnings DateN/A
Forward Dividend & Yield0.28 (1.40%)
Ex-Dividend DateDec 29, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • CHMP Recommends EU Approval of Chugai’s Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Business Wire

    CHMP Recommends EU Approval of Chugai’s Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)

    Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche has received notification that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of the pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody Enspryng® (satralizumab), created by Chugai, as the first subcutaneous treatment option for adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy (IST).

  • Chugai’s Enspryng Approved in Taiwan as First Approved Medicine for Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Business Wire

    Chugai’s Enspryng Approved in Taiwan as First Approved Medicine for Neuromyelitis Optica Spectrum Disorder (NMOSD)

    Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced Chugai Pharma Taiwan Ltd., a wholly-owned subsidiary of Chugai, obtained an import drug license from the Taiwan Food and Drug Administration (TFDA) for Chugai’s Enspryng® for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult and adolescent over 12 years old patients who are anti-aquaporin-4 (AQP4) antibody positive.

  • New Data of Chugai’s Enspryng (Satralizumab) on Risk and Severity of Relapse in Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Business Wire

    New Data of Chugai’s Enspryng (Satralizumab) on Risk and Severity of Relapse in Neuromyelitis Optica Spectrum Disorder (NMOSD)

    Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced the presentation of new Enspryng® (generic name: satralizumab [genetical recombination]) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MS Virtual 2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy and safety data on the continued effect of Enspryng on reducing the risk of NMOSD relapse as well as its benefit-risk profile. Enspryng is a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody created by Chugai.